Crossmark

Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis

Published Online: 2025-03-14

Published Print: 2025-06

Authors

Cheah, Mark C. C. https://orcid.org/0000-0002-5448-232X
Crane, Harry

George, Jacob
Funding

Funding for this research was provided by:

University of Sydney
License Information

Text and Data Mining valid from 2025-03-14

Version of Record valid from 2025-03-14
More Information

Article History

Received: 17 December 2024

Accepted: 15 February 2025

First Online: 14 March 2025

Declarations

:

: Professor Jacob George has served on advisory boards and received speaker fees for Novo Nordisk, Boehringer Ingelheim, Roche, Astra Zeneca, and Pfizer. Mark Cheah and Harry Crane have no financial or non-financial disclosures.

Document is current